2 days ago by cnbc.com
"How quickly that can be deployed will depend on some of the early data that we have, some animal data, what we will see in patients," Regeneron CEO Leonard Schleifer told CNBC. read more...
"How quickly that can be deployed will depend on some of the early data that we have, some animal data, what we will see in patients," Regeneron CEO Leonard Schleifer told CNBC.
Regeneron stock is one of the top names in the markets this year “thanks” to the coronavirus. But microbial threats down the line ensure that REGN is no flash in the pan.More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid Check Out These 7 Fast-Growing Stocks to Buy Today 10 Stocks That Every 20-Year-Old Should Buy 7 Losers To Buy Today For Big Wins Tomorrow